This content is machine translated Lipid management: ESC/EAS guideline update 2025 New recommendations on CVD risk classification, lipid lowering in statin intolerance and hoFH The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guideline update on the management of dyslipidemia continues to focus largely on how best to manage lipid levels to...…
View Post 6 min This content is machine translated Cardiovascular risk Bad news for young men with T2D Cardiovascular disease ( CVD) remains the leading cause of death and disease worldwide, and people with type 1 or type 2 diabetes are at higher risk than the general population....…
View Post 5 min This content is machine translated Arterial hypertension: ESC guideline 2024 in focus New category “elevated blood pressure” – what are the therapeutic implications? According to the guideline of the European Society of Cardiology (ESC), which was updated last year, blood pressure values of 120-139/70-89 mmHg are considered “raised blood pressure”. Drug therapy is...…
View Post 4 min This content is machine translated Prurigo nodularis Retrospective analyses of large data sets from everyday practice Prurigo nodularis (PN) is a chronic inflammatory skin disease that manifests itself as extremely itchy hard nodules. Prof. Dr. med. Dr. rer nat. Enno Schmidt from the University Hospital Schleswig-Holstein...…
View Post 15 min This content is machine translated Current status and future prospects Cell and gene therapies in modern cardiology Cell and gene therapies are considered highly innovative but also challenging approaches in modern cardiology. While early hopes for adult stem cells from bone marrow or skeletal muscle were largely...…
View Post 6 min This content is machine translated Journal Club CVD: Update on risk factors and prevention Cardiovascular disease (CVD) has a high prevalence worldwide and is associated with significant morbidity and mortality. Several secondary analyses have been published in the past two years. While Magnussen et...…
View Post 5 min This content is machine translated LDL cholesterol level On the way to the (LDL-C) target Cardiovascular disease ( CVD) is the leading cause of death worldwide. Lowering the level of LDL cholesterol (LDL-C) in the blood reduces the risk of CVD such as heart attacks…
View Post 5 min This content is machine translated Nanobiomaterials Revolutionary approaches to the treatment of cardiac arrhythmias Nanobiomaterials offer a revolutionary opportunity to improve the treatment of cardiac arrhythmias. From targeted drug delivery to tissue regeneration and continuous monitoring, they open up new horizons for personalized medicine.…
View Post 5 min This content is machine translated COPD and CVD in PRISm patients Exacerbations damage the lungs – and the heart COPD exacerbations not only contribute to the progression of lung disease, but can also increase the risk of cardiovascular disease (CVD). An American research group investigated the relationship between COPD…
View Post 4 min This content is machine translated Acute myocardial infarction and heart failure in young diabetics Type 2 with a poor risk profile for CVD Type 1 and type 2 diabetes differ in many ways, but both types are strongly associated with a high risk of cardiovascular complications. T2D at a young age is considered…
View Post 4 min This content is machine translated SGLT-2-i in type 2 diabetes and CVD Cardioprotective mechanisms of action of empagliflozin – what’s new? Empagliflozin is known to reduce the risk of atherosclerotic cardiovascular disease (CVD) in people with type 2 diabetes and high cardiovascular risk. The mechanisms underlying these effects are not yet…
